The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $15.87 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback